



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** October 17, 2008

**To:** Primary Clinical Research Associates

**From:** Sara Braun  
Research Protocol Specialist III

**Re:** N057K, Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

The Eligibility Checklist has been revised to reflect Mayo Florida rather than Mayo Jacksonville. Also, the Baseline Tissue Specimen Submission Form, Baseline Optional Blood Specimen Submission Form, Cycle 1 Active Monitoring Mandatory Blood Specimen Submission Form, and Phase II Mandatory Blood Specimen Submission Form have been revised in conjunction with Addendum 1. **NOTE: The effective date of October 17, 2008 will remain the same.** Please replace your current versions of these forms with the revised versions.

If you have any questions, please feel free to contact me.

Enclosure